Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Moriarty

Showing results (371-380 of 427) with videos related to

Pageof 43
Sort By:
Journal of Clinical Lipidology|June 3, 2017
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugsClaudia Stefanutti, Ulrich Julius, Gerald F Watts, et al.
Journal of Thoracic Imaging|August 8, 2014
ACR Appropriateness Criteria® nontraumatic aortic disease, Sanjeeva P Kalva, Karin E Dill, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Circulation|November 3, 2025
Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE TrialRobert A Lookstein, Stavros V Konstantinides, Ido Weinberg, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Journal of Clinical Lipidology|March 21, 2020
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Target gene regulatory network of miR-497 in angiosarcomaAnnaleigh Benton, Emma Terwilliger, Noah M Moriarty, et al.
Molecular Cancer Research : MCR|May 21, 2024
miR-497 Target Gene Regulatory Network in AngiosarcomaAnnaleigh Benton, Noah M Moriarty, Emma Terwilliger, et al.
Journal of Clinical Lipidology|July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemiaEwa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.
International Journal of Cardiology|December 3, 2014
Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patientsMarta Michalska-Kasiczak, Amirhossein Sahebkar, Dimitri P Mikhailidis, et al.
Pageof 43

Showing results (371-380 of 427) with videos related to

Sort By:
Pageof 43
Journal of Clinical Lipidology|June 3, 2017
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugsClaudia Stefanutti, Ulrich Julius, Gerald F Watts, et al.
Journal of Thoracic Imaging|August 8, 2014
ACR Appropriateness Criteria® nontraumatic aortic disease, Sanjeeva P Kalva, Karin E Dill, et al.
Journal of Clinical Lipidology|May 22, 2016
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trialPatrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, et al.
Circulation|November 3, 2025
Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE TrialRobert A Lookstein, Stavros V Konstantinides, Ido Weinberg, et al.
Journal of Clinical Lipidology|December 22, 2015
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Journal of Clinical Lipidology|March 21, 2020
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trialPatrick M Moriarty, Paul D Thompson, Christopher P Cannon, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Target gene regulatory network of miR-497 in angiosarcomaAnnaleigh Benton, Emma Terwilliger, Noah M Moriarty, et al.
Molecular Cancer Research : MCR|May 21, 2024
miR-497 Target Gene Regulatory Network in AngiosarcomaAnnaleigh Benton, Noah M Moriarty, Emma Terwilliger, et al.
Journal of Clinical Lipidology|July 28, 2022
Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemiaEwa Karwatowska-Prokopczuk, Jean-Claude Tardif, Daniel Gaudet, et al.
International Journal of Cardiology|December 3, 2014
Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patientsMarta Michalska-Kasiczak, Amirhossein Sahebkar, Dimitri P Mikhailidis, et al.
Pageof 43